Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 1/2017

29.01.2016 | Case Report

A Case of Signet Ring Cell Carcinoma of the Gallbladder Which Was Treated by Aggressive Surgery and Intensive Adjuvant Chemotherapy

verfasst von: Masatsugu Hiraki, Junji Ueda, Keita Kai, Takao Ide, Masako Asai, Takao Ohtsuka, Naohiko Kohya, Shinsuke Mukai, Kenji Kitahara, Hirokazu Noshiro

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

Carcinoma of the gallbladder is the most common malignancy of the biliary tract. It is a highly fatal disease with a poor prognosis [1]. Intensive treatment, including surgery and effective chemotherapy, is therefore important for prolonging patient survival. Adenocarcinoma is the most common histological type of gallbladder carcinoma (80–95 %) [1], while signet ring cell carcinoma (SRCC) is extremely rare. In the digestive system, SRCC mostly occurs in the stomach (86.8 %). SRCC of the gallbladder is extremely rare (2.5 %) [2, 3]. As a result, the biological features and treatment strategies have not been well documented due to the small number of previous reports. In the present study, we report the case of a patient with gallbladder SRCC who was treated with aggressive surgery and intensive adjuvant chemotherapy using gemcitabine and S-1. …
Literatur
1.
Zurück zum Zitat Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. The Lancet Oncology. 2003;4(3):167–76.CrossRefPubMed Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. The Lancet Oncology. 2003;4(3):167–76.CrossRefPubMed
2.
Zurück zum Zitat Hiraki M, Yakushiji H, Hashiguchil K, Harada S, Okada K, Goto Y, et al. Signet ring cell carcinoma of the lower bile duct with rapid growth: report of a case. Hepato-gastroenterology. 2007;54(79):1922–4.PubMed Hiraki M, Yakushiji H, Hashiguchil K, Harada S, Okada K, Goto Y, et al. Signet ring cell carcinoma of the lower bile duct with rapid growth: report of a case. Hepato-gastroenterology. 2007;54(79):1922–4.PubMed
3.
Zurück zum Zitat Pathology TJSo. Annual of the pathological autopsy cases in Japan. In., edn. Tokyo; 1997; pp. 1112-1185, 1998; pp. 1102- 1174, 1999; pp .1138-1210, 2000; pp .1196-1268, 2001; pp .1254-1327. (In Japanese) Pathology TJSo. Annual of the pathological autopsy cases in Japan. In., edn. Tokyo; 1997; pp. 1112-1185, 1998; pp. 1102- 1174, 1999; pp .1138-1210, 2000; pp .1196-1268, 2001; pp .1254-1327. (In Japanese)
4.
Zurück zum Zitat Edge SB. BD, Compton CC, Fritz AG, Greene FL, Trotti A, editors: AJCC cancer staging manual (7th ed). New York, NY: Springer; 2010. Edge SB. BD, Compton CC, Fritz AG, Greene FL, Trotti A, editors: AJCC cancer staging manual (7th ed). New York, NY: Springer; 2010.
5.
Zurück zum Zitat Mondal SK. Signet ring cell carcinoma of gallbladder with celiac lymph node metastasis in a young man. Journal of cancer research and therapeutics. 2010;6(3):379–81.CrossRefPubMed Mondal SK. Signet ring cell carcinoma of gallbladder with celiac lymph node metastasis in a young man. Journal of cancer research and therapeutics. 2010;6(3):379–81.CrossRefPubMed
6.
Zurück zum Zitat Karabulut Z, Yildirim Y, Abaci I, Ilgici D, Ozyilkan O. Signet-ring cell carcinoma of the gallbladder: a case report. Advances in therapy. 2008;25(5):520–3.CrossRefPubMed Karabulut Z, Yildirim Y, Abaci I, Ilgici D, Ozyilkan O. Signet-ring cell carcinoma of the gallbladder: a case report. Advances in therapy. 2008;25(5):520–3.CrossRefPubMed
7.
Zurück zum Zitat Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Annals of surgery. 2009;250(6):878–87.CrossRefPubMed Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Annals of surgery. 2009;250(6):878–87.CrossRefPubMed
8.
Zurück zum Zitat Hugen N, Verhoeven RH, Lemmens VE, van Aart CJ, Elferink MA, Radema SA, et al. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. International journal of cancer Journal international du cancer. 2015;136(2):333–9.CrossRefPubMed Hugen N, Verhoeven RH, Lemmens VE, van Aart CJ, Elferink MA, Radema SA, et al. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. International journal of cancer Journal international du cancer. 2015;136(2):333–9.CrossRefPubMed
9.
Zurück zum Zitat Dursun N, Escalona OT, Roa JC, Basturk O, Bagci P, Cakir A, et al. Mucinous carcinomas of the gallbladder: clinicopathologic analysis of 15 cases identified in 606 carcinomas. Archives of pathology & laboratory medicine. 2012;136(11):1347–58.CrossRef Dursun N, Escalona OT, Roa JC, Basturk O, Bagci P, Cakir A, et al. Mucinous carcinomas of the gallbladder: clinicopathologic analysis of 15 cases identified in 606 carcinomas. Archives of pathology & laboratory medicine. 2012;136(11):1347–58.CrossRef
10.
Zurück zum Zitat Kohya N, Miyazaki K. Hepatectomy of segment 4a and 5 combined with extra-hepatic bile duct resection for T2 and T3 gallbladder carcinoma. Journal of surgical oncology. 2008;97(6):498–502.CrossRefPubMed Kohya N, Miyazaki K. Hepatectomy of segment 4a and 5 combined with extra-hepatic bile duct resection for T2 and T3 gallbladder carcinoma. Journal of surgical oncology. 2008;97(6):498–502.CrossRefPubMed
11.
12.
Zurück zum Zitat Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer chemotherapy and pharmacology. 2006;57(5):647–53.CrossRefPubMed Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer chemotherapy and pharmacology. 2006;57(5):647–53.CrossRefPubMed
13.
Zurück zum Zitat Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer chemotherapy and pharmacology. 2008;62(5):849–55.CrossRefPubMed Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer chemotherapy and pharmacology. 2008;62(5):849–55.CrossRefPubMed
14.
Zurück zum Zitat Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer science. 2013;104(9):1211–6.CrossRefPubMed Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer science. 2013;104(9):1211–6.CrossRefPubMed
15.
Zurück zum Zitat Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. The New England journal of medicine. 2010;362(14):1273–81.CrossRefPubMed Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. The New England journal of medicine. 2010;362(14):1273–81.CrossRefPubMed
16.
Zurück zum Zitat Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2004;15(9):1339–43.CrossRef Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2004;15(9):1339–43.CrossRef
17.
Zurück zum Zitat Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(10):2332–8.CrossRef Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(10):2332–8.CrossRef
18.
Zurück zum Zitat Albores-Saavedra J, Cruz-Ortiz H, Alcantara-Vazques A, Henson DE. Unusual types of gallbladder carcinoma. A report of 16 cases. Archives of pathology & laboratory medicine. 1981;105(6):287–93. Albores-Saavedra J, Cruz-Ortiz H, Alcantara-Vazques A, Henson DE. Unusual types of gallbladder carcinoma. A report of 16 cases. Archives of pathology & laboratory medicine. 1981;105(6):287–93.
19.
Zurück zum Zitat Albores-Saavedra J, Nadji M, Henson DE. Intestinal-type adenocarcinoma of the gallbladder. A clinicopathologic study of seven cases. The American journal of surgical pathology. 1986;10(1):19–25.CrossRefPubMed Albores-Saavedra J, Nadji M, Henson DE. Intestinal-type adenocarcinoma of the gallbladder. A clinicopathologic study of seven cases. The American journal of surgical pathology. 1986;10(1):19–25.CrossRefPubMed
20.
Zurück zum Zitat Ahmad Z, Qureshi A. Primary signet ring cell carcinoma of gall bladder: report of an extremely rare histological type of primary gall bladder carcinoma. BMJ case reports. 2010;2010. Ahmad Z, Qureshi A. Primary signet ring cell carcinoma of gall bladder: report of an extremely rare histological type of primary gall bladder carcinoma. BMJ case reports. 2010;2010.
Metadaten
Titel
A Case of Signet Ring Cell Carcinoma of the Gallbladder Which Was Treated by Aggressive Surgery and Intensive Adjuvant Chemotherapy
verfasst von
Masatsugu Hiraki
Junji Ueda
Keita Kai
Takao Ide
Masako Asai
Takao Ohtsuka
Naohiko Kohya
Shinsuke Mukai
Kenji Kitahara
Hirokazu Noshiro
Publikationsdatum
29.01.2016
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 1/2017
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-016-9804-x

Weitere Artikel der Ausgabe 1/2017

Journal of Gastrointestinal Cancer 1/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.